KRAS and non-small cell lung carcinoma: The KEYNOTE-042 trial evaluated pembrolizumab as a first-line treatment in NSCLC patients with PD-L1 expression on ≥1% of tumor cells (TC) and showed improved overall survival compared to chemotherapy, regardless of KRAS mutations status.